Saudi MOH and CDC schedules, every vaccine's type, timing and contraindications, special groups, post-exposure prophylaxis and cold chain — matched to the exam bank.
| Visit | Vaccines |
|---|---|
| Birth | BCG (ID) + HepB dose 1 |
| 2 months | Hexavalent (DTaP-IPV-Hib-HepB) + PCV + Rotavirus |
| 4 months | Hexavalent + PCV + Rotavirus |
| 6 months | Hexavalent + PCV + OPV |
| 9 months | Measles (monovalent) + MCV4 (MenACWY conjugate) |
| 12 months | MMR 1 + PCV booster + OPV + MCV4 |
| 18 months | DTaP-IPV-Hib booster + OPV + MMR 2 + Varicella 1 + HepA 1 |
| 24 months | HepA 2 |
| 4–6 years (school entry) | DTaP + OPV + MMR + Varicella 2 |
| School / adolescent | Tdap booster (with MCV4 in school programme); HPV for girls (added 2022) |
Annual inactivated influenza vaccine from 6 months (priority: chronic disease, asthma, SCD, Down syndrome). Rotavirus = 2 oral doses (2 and 4 m). Polio = IPV inside hexavalent plus OPV at 6, 12, 18 m and 4–6 y. Some recent MOH cards move varicella dose 1 to 12 m; follow the card in hand.
| Item | Saudi MOH | CDC (USA) |
|---|---|---|
| BCG | At birth | Not routine |
| Polio | IPV (hexavalent) + OPV | IPV only: 2, 4, 6–18 m, 4–6 y |
| HepB | Birth + hexavalent 2, 4, 6 m | Birth, 1–2 m, 6–18 m |
| Rotavirus | 2 doses (2, 4 m) | RV1 2 doses or RV5 3 doses (2, 4, 6 m) |
| Measles | Monovalent 9 m, MMR 12 and 18 m | MMR 12–15 m and 4–6 y |
| Varicella | 18 m and 4–6 y | 12–15 m and 4–6 y |
| HepA | 18 and 24 m | 2 doses from 12–23 m, 6 m apart |
| MenACWY | Infancy: 9 and 12 m | 11–12 y + booster at 16 y |
| DTaP booster | 18 m and 4–6 y | 15–18 m and 4–6 y; Tdap 11–12 y |
| HPV | Girls | All adolescents 11–12 y (from 9 y) |
| PCV | 2, 4, 6 m + 12 m | 2, 4, 6 m + 12–15 m |
| Live attenuated | Inactivated / subunit / toxoid |
|---|---|
| BCG (ID) OPV, rotavirus, oral typhoid Ty21a (oral) MMR, varicella, MMRV, yellow fever (SC) LAIV (intranasal) | DTaP/Tdap/Td, IPV, Hib, HepB, HepA, PCV, PPSV23, MenACWY, MenB, HPV, injectable influenza, Vi typhoid, rabies, COVID mRNA (IM) |
Live vaccines are the ones avoided in pregnancy and significant immunosuppression.